静脉注射免疫球蛋白联合免疫抑制剂治疗炎性肌病难治性吞咽困难的长期疗效:回顾性分析
结果显示EAT-10评分下降、吞咽功能改善,52周随访时12例患者参数稳定或进一步改善,且观察到激素节约效应。
要点
- IVIG 2 g/kg每月1天、连续3个月可改善IIM相关难治性吞咽困难。
- EAT-10联合FEES可用于诊断和评估吞咽困难治疗反应。
- FEES-吞咽困难组抗PM/Scl 75/100抗体更常见,抗Jo1抗体少见。
核心结论
- 每月1天IVIG 2 g/kg、连续3个月的方案对EAT-10联合FEES评估的IIM相关难治性吞咽困难有效。
主要发现
- 3次每月IVIG后EAT-10评分下降,推进失败完全恢复,固体和液体滞留百分比逐步降低。
- 52周随访时12例患者上述参数稳定或进一步改善,并观察到徒手肌力测试改善和IVIG的激素节约效应。
- FEES-吞咽困难组抗PM/Scl 75/100抗体更常见,抗Jo1抗体少见。
关键数值与推荐
- 吞咽困难定义为EAT-10评分≥3且FEES至少一项异常(推进失败、固体或液体滞留)。
- IVIG方案为1天2 g/kg,间隔1个月重复,共3个月。
临床怎么用
- 对高剂量糖皮质激素联合甲氨蝶呤和/或硫唑嘌呤难治的IIM吞咽困难,可考虑加用每月1天IVIG 2 g/kg、连续3个月。
- 治疗评估可联合EAT-10和FEES。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Dysphagia is a life-threating manifestation of idiopathic inflammatory myopathies (IIM). However, we lack a univocal protocol for its treatment. The aim of this retrospective analysis was to evaluate the effectiveness of a step-up strategy by adding a 1-day pulse of IVIGs to immunosuppressants in IIM patients with refractory dysphagia diagnosed by Eating Assessment Tool (EAT)-10 and fibreoptic endoscopic evaluation of swallowing (FEES). METHODS: Dysphagia was defined as a pharyngo-oesophageal disturbance associated with EAT-10 score ≥3 and at least one FEES abnormality among propulsion failure, solid or liquid stasis. Eighteen out of 154 IIM patients had FEES-confirmed dysphagia and underwent 1 day IVIG 2 g/kg repeated 1 month apart for 3 months, because of dysphagia refractory to high-dose glucocorticoids with methotrexate and/or azathioprine. Clinical characteristics along with myositis-specific antibodies and muscle histopathological findings were studied in FEES-dysphagia IIM and IIM control patients. RESULTS: After three monthly doses of IVIG, EAT-10 score dropped with complete recover of defective propulsion and progressive decrease in percentage of both solid and liquid stasis. At 52-weeks' follow-up, reached in 12 patients, all these parameters were stable or further improved. An improvement in manual muscle strength test and a steroid-sparing effect of IVIG were also observed. Anti-PM/Scl 75/100 antibodies were much more frequent in the FEES-dysphagia group, while anti-Jo1 antibody was rarely detected. CONCLUSION: Our treatment schedule with 2 g/kg IVIG was effective for IIM-associated refractory dysphagia assessed by the combination of EAT-10 and FEES. These findings need to be prospectively tested in a larger cohort of IIM patients.
引用
- Giannini M, Fiorella ML, Tampoia M, et al. Long-term efficacy of adding intravenous immunoglobulins as treatment of refractory dysphagia related to myositis: a retrospective analysis. Rheumatology (Oxford). 2021. PMID: 32911543. doi:10.1093/rheumatology/keaa443
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。